Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206530 | 0.90 | TSHR (0.45) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7207163 | 0.89 | MMP1 (0.45) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7202596 | 0.89 | MMP1 (0.54) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7199674 | 0.89 | MMP1 (0.42) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7204544 | 0.87 | MMP1 (0.41) | MMP1MMP13FAAHALDH1A1ADAMTS4 | |
| SCHEMBL7199692 | 0.85 | PARP10 (0.41) | MMP1MMP13 | |
| SCHEMBL7208181 | 0.84 | MMP13 (0.56) | MMP1MMP13ADAMTS4 | |
| SCHEMBL7199646 | 0.84 | MMP1 (0.43) | MMP1MMP13FAAHALDH1A1LMNA | |
| SCHEMBL7292292 | 0.83 | AKR1C3 (0.45) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7204562 | 0.83 | MMP13 (0.51) | MMP1MMP13ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP1 8/4885MMP13 4/4885FAAH 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.